Industrial biotechnology · Chemicals at the edge of healthcare
Solugen
A Houston company that turns corn sugar into industrial chemicals using an enzyme its co-founder found in pancreatic cancer cells. The evidence behind it is plants, offtake partners and a federal loan commitment, not clearances or trials.
A poker game in Dallas
Gaurab Chakrabarti was an MD and PhD candidate at UT Southwestern, working on why pancreatic cancer cells flood themselves with hydrogen peroxide. At a long running poker game, he kept talking about it to Sean Hunt, an MIT chemical engineering student who was dating, and later married, Chakrabarti’s dissection lab partner.
Hunt was studying how to make the same molecule with metal catalysts, at industrial scale. He did not believe an enzyme could survive a chemical plant. “I was, like, ‘There’s no way an enzyme could be used in an industrial, long-scale chemical process,’” he told Forbes in 2020. Chakrabarti kept talking. Hunt kept losing at cards.
In 2016 they entered the MIT $100K competition, made the finals and won $10,000. That money bought PVC pipe at Home Depot and pumps off eBay. The reactor they built behind Dallas Love Field made five gallons of hydrogen peroxide a day.
Then a Facebook group of float spa owners found the pitch video. Float spas keep their water clean with peroxide, and they wanted a supplier. By December 2016 the two were selling $10,000 of peroxide a month out of the back of Hunt’s Subaru.
What the healthcare connection is, and what it is not
The healthcare thread here is real and it is narrow. The enzyme came out of cancer biology. The co-founder and chief executive is a physician scientist. The first product, hydrogen peroxide, is an antiseptic and disinfectant, and Solugen’s first branded consumer product was a line of sanitizing wipes, Ode to Clean, made with Diamond Wipes and sold to that partner in 2018. In 2020 the company blended its peroxide with ethanol to make hand sanitizer and gave most of it away to hospitals and clinics through Operation USA. A current product family, Altiv, goes into skincare, household cleaning and sanitizing wipes.
What it is not is a healthcare company in any regulated sense. There is no FDA 510(k) or premarket approval record, no registered clinical trial, and no NIH or NSF award. Nothing Solugen sells is a drug, a device or a diagnostic. The markets it names are oilfield produced water, water treatment, agriculture, concrete, defense, and home and personal care.
Read Solugen as an industrial manufacturer with a biomedical origin story. Judge it on tons shipped, plants finished and money that closed.
Wipes as a Trojan horse
Y Combinator took them in the Winter 2017 batch, one of the rare chemistry companies in a software accelerator. The wipes deal followed. Chakrabarti was blunt with Forbes about why: the point was never wipes. It was the supply contract and the credibility to sell to industrial buyers.
It worked. In fall 2018 they hired a salesman out of Schlumberger and sold the same chemistry as a treatment for the contaminated salt water that oil and gas wells throw off. By 2019 revenue was $12 million, roughly 80 percent of it from wastewater, and they had bought a decommissioned Houston chemical plant for close to $3 million to become Bioforge Houston.
The Minnesota bet
In November 2023 Solugen and ADM announced a plant next to ADM’s corn complex in Marshall, Minnesota, fed by two dextrose pipelines. Ground was broken on April 11, 2024, for a 500,000 square foot building with three modular trains and a stated capacity of up to 120 kilotonnes a year. Houston, at roughly 10,000 to 12,000 tonnes a year, is an order of magnitude smaller.
On June 13, 2024 the Department of Energy Loan Programs Office announced a conditional commitment for a $213.6 million loan guarantee to Bioforge Marshall LLC. Minnesota added $760,000 from its Job Creation Fund and $15 million from the Minnesota Forward Fund. Production was to start in fall 2025.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| FDA records | No 510(k) and no premarket approval record for Solugen or its products as of Sep 22, 2026. | Not found |
| Clinical trials | No registered trials. The company does not claim any. | Not found |
| Federal research grants | No NIH and no NSF awards on record. Federal support has come through the Department of Energy and, per the company, a 2023 Defense Department contract. | Not found |
| DOE loan guarantee | Conditional commitment of $213.6 million announced Jun 13, 2024 for Bioforge Marshall LLC. The company release says “certain technical, legal, environmental, and financial conditions, including negotiation of definitive financing documents, must be satisfied before funding of the loan guarantee.” A DOE record posted Nov 7, 2024 says the office “has decided to provide a loan guarantee to construct and operate a bio-feedstock-based facility” for gluconic acid. No record of a closed loan was found as of Sep 22, 2026. | Public record |
| State incentives | $760,000 from the Minnesota Job Creation Fund, Apr 2024, plus $15 million from the Minnesota Forward Fund, Jun 13, 2024. | Public record |
| Plants | Bioforge Houston online 2021, about 10,000 to 12,000 tonnes a year. Blending site in Slaton, Texas, 2019. Bioforge Marshall, groundbreaking Apr 11, 2024, target fall 2025 and up to 120 kilotonnes a year. No independent confirmation of Marshall reaching production was found. | Public record |
| Feedstock and offtake partners | ADM supplies dextrose by dedicated pipeline. Sasol Chemicals signed an Oct 2023 agreement to evaluate Solugen chelating agents. Kurita America announced a Jul 2024 collaboration and ships a Tower NG cooling line using a Solugen inhibitor. Diamond Wipes remains a peroxide customer. | Partner-stated |
| Peer reviewed work | One paper found: Gomez-Uribe, Gado and Islamov, PLOS Computational Biology, Jun 2025, on protein design methods. Its acknowledgments read “We are grateful to Solugen for supporting this work.” | Public record |
| Revenue | $12 million in 2019 per Forbes. Later described as “on pace for over $100 million in revenue across more than 30 active customers” in 2022. No audited figures are public. | Company-stated |
| Equity raised | Four Form D filings, 2018 to 2021, report $425,869,925 sold. Press accounts in 2023 and 2024 put venture funding above $640 million, and one 2025 analysis at over $850 million including debt. | Filed below announced |
Read plainly: the technology works at the scale of one finished plant, and the commercial pull shows up as named partners rather than a customer list. The larger claims, a second plant ten times the size of the first and a federal loan guarantee behind it, were announced in 2024 and have not been shown finished in the public record.
What to watch
- Whether the DOE loan guarantee closed and was funded. A conditional commitment is an intent, not a wire transfer.
- First production at Bioforge Marshall. The target was fall 2025, with no confirmation a year later.
- A Form D covering the reported $200 million round of October 2022. None appears on EDGAR.
- Whether the personal care line, Altiv, yields a named customer rather than an evaluation agreement.
- Whether the company moves to licensing its process rather than owning plants.
In their words
“The first molecule that we discovered in pancreatic cancer was hydrogen peroxide.”
Gaurab Chakrabarti, co-founder and CEO, My Climate Journey podcast, 2021 · Interview
“My background is not in biotech, so I’m kind of the recovering biotech skeptic.”
Sean Hunt, co-founder and CTO, MIT News, 2019 · Independent
“There’s about 400 float spas in the U.S., and they’re all on one Facebook group, and one owner saw our MIT $100K pitch video and shared it to the Facebook group.”
Sean Hunt, MIT News, 2019 · Independent
“It was a Trojan Horse for us, with an aim of selling the brand and getting a supplier contract.”
Gaurab Chakrabarti on the Ode to Clean wipes deal, Forbes, 2020 · Independent
“We go head to head with phosphates.”
Sean Hunt on pricing, Forbes, 2020 · Independent
“We ended up raising 357 million dollars at a 1.8 billion dollar valuation.”
Gaurab Chakrabarti, My Climate Journey podcast, recorded Sep 10, 2021 · Interview
“That’s where we put all of our focus, is figuring out how to decarbonize the chemicals industry.”
Gaurab Chakrabarti, Marshall Independent, 2024 · Independent
“American manufacturing is at a turning point, and we are proud to have the opportunity to work with the DOE in bringing critical chemical production capabilities onshore to communities like Marshall.”
Gaurab Chakrabarti, June 2024 loan guarantee release · Company release
Related companies
Sources
- Public recordForm D, Solugen, Inc., CIK 0001756965, four filings
- Public recordDOE/EA-2246, Solugen, Inc., Bioforge Marshall Project
- Public recordGovernor Walz announces $213 million for a Marshall biomanufacturing facility
- Public recordDesigning diverse and high-performance proteins with a large language model in the loop
- IndependentCleaning up hydrogen peroxide production
- IndependentHow two young scientists built a $250 million business using yeast to clean up wastewater
- IndependentHouston chemicals company raises $357M, claims unicorn status
- IndependentSolugen to expand biobased chemical production with ADM
- IndependentJust the beginning for Solugen
- IndependentSolugen scores $214 million loan from DOE to make chemicals from corn sugar not petroleum
- IndependentSolugen receives $213M DOE loan for biochemical facility
- InterviewEpisode 175: Gaurab Chakrabarti and Sean Hunt, Solugen
- CompanySolugen secures conditional commitment for $213.6M DOE loan guarantee
- CompanySolugen breaks ground on Bioforge Marshall facility
- PartnerSasol Chemicals and Solugen to evaluate sustainable care chemicals ingredients
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
